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Osteogenesis imperfecta (OI) is generally caused by a dominant mutation in Collagen I, encoded by the genes 
COL1A1 and COL1A2. To date there is no satisfactory therapy for OI, but inactivation of the mutant allele through 
small interfering RNAs (siRNA) is a promising approach, as siRNAs targeting each allele of a polymorphism 
could be used for allele-specific silencing irrespective of the location of the actual mutations. In this study we 
examined the allele dependent effects of several tiled siRNAs targeting a region surrounding an exonic COL1A2 
T/C polymorphism (rs1800222) in heterozygous primary human bone cells. Relative abundances of COL1A2 
alleles were determined by cDNA sequencing and overall COL1A2 abundance was analyzed by quantitative 
PCR. One of the siRNAs decreased overall COL1A2 abundance by 71% of which 75% was due to silencing of the 
targeted T-allele. In conclusion, allele-preferential silencing of Collagen type I genes may be a future therapeutic 
approach for OI. 
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INTRODUCTION 
Osteogenesis imperfecta (OI) is a heterogeneous 
disease of the connective tissue with an incidence of 
approximately 1/10 000. The principal sign of OI is 
fragile bones with multiple fractures, but the disease 
can affect many other tissues as well. The mildest form 
of OI (type I) is often due to a null allele mutation (1), 
while severe and lethal forms (type II-VII) generally 
have a qualitative collagen defect (2). More than 90% of 
OI is caused by a dominant mutation in collagen type I, 
which is the most abundant protein in connective tis-
sue. Approximately 90% of the organic matrix of bone 
consists of collagen I, where it provides both the 
framework for mineralization and the tensile strength 
that gives bone elasticity. Collagen I is comprised of 
two α1(I) chains and one α2(I) chain, encoded by the 
genes  COL1A1 and COL1A2, respectively. The three 
monomers twist together in a zipper like fashion to 
create a triple helix which has a highly repetitive 
structure, (Gly-X-Y)n, with the glycine residue at every 
third position facing the confined space in the centre of 
the helix. The most common cause of OI is a mutation 
affecting a glycine residue.  
To date, there is no satisfactory therapy for pa-
tients with OI. Many patients are treated with 
bisphosphonates, which there is some support for in 
some clinical trials (3). However, the results are insuf-
ficient and little is known about which patients benefit 
from this treatment and which do not. It is not known 
if treatment with other osteoporosis drugs would be a 
better alternative or would potentially complement the 
bisphosponate treatment in patients with OI. Consid-
ering mutations in severe OI act in a dominant fashion, 
a therapeutic vision is to convert a severe OI type to a 
type I OI by silencing the mutated allele. For COL1A1, 
this would convert a severe phenotype to a mild OI 
type I, while individuals who are heterozygous for 
null mutations in COL1A2 are phenotypically normal 
(4). One attractive avenue is allele specific silencing 
through RNA interference (RNAi), which in contrast to 
other methods of manipulation has a high and specific 
inhibition (5).  
RNA interference is the process by which double 
stranded exogenous RNA elicit degradation of cellular 
RNA with sequence complementary to one of the 
strands. Following findings that antisense RNA de-
creased abundance of complementary mRNA (6) and 
later discoveries by Fire et al. (7), RNA interference has 
been developed into an extensively used method to 
decrease the abundance of specific genes. In 1999, 
small interfering RNAs (siRNAs) were discovered as 
endogenous molecules mediating RNA interference in 
plants (8) and in 2001 it was shown that exogenous 
double stranded siRNAs efficiently reduced mRNA Int. J. Med. Sci. 2008, 5 
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levels in animal cells in vitro (9). Since these seminal 
discoveries, the siRNA technology has been further 
developed and siRNAs are now invaluable as they 
enable partial gene knockout in vitro as well as in vivo 
(10).  
Recent studies have reported successful allele 
specific gene silencing by siRNAs able to discriminate 
between single nucleotide variants within mRNAs 
(11-13). These studies suggest that siRNAs may be 
interesting to explore as therapeutics in monogenic 
dominant disorders such as OI, where the dysfunc-
tional allele could be targeted specifically. Indeed, al-
lele-preferential suppression mediated by RNAi has 
been described in vitro for human COL1A1 allele con-
structs transfected into the primate kidney cell line 
COS-7 and for endogenous COL1A1 in human mes-
enchymal progenitor cells (14). Additionally, a 
splice-site mutated COL1A2 allele has been preferen-
tially silenced in fibroblasts from a patient suffering 
from a type IV OI (15).  
To date over 800 mutations have been described 
as causative of OI (2), making it labour intensive to 
design siRNAs for every separate mutation. In het-
erozygous individuals for a common polymorphism, 
siRNAs targeting each allele of COL1A2 as well as 
COL1A1 could be used for allele specific silencing ir-
respective of the location of the actual mutations. In 
this study we have examined the allele dependent ef-
fects of seven tiled siRNAs targeting a region sur-
rounding an exonic COL1A2  SNP (rs1800222), for 
which the cells were heterozygous.  
MATERIALS AND METHODS 
siRNA design 
Seven tiled 21 nucleotide long siRNAs were de-
signed. Each siRNA had antisense strands (AS) per-
fectly complementary to the T-allele of rs1800222 
(Figure 1). siRNAs were purchased from Ambion as 
double stranded RNA molecules. Each strand of 
siRNAs had a two-basepair overhang in the 3'-end 
(always UU for sense strand) (Figure 1 illustrates the 
active antisense strand). Negative control siRNAs were 
purchased from Invitrogen and were: Stealth™ RNAi 
Negative controls (part numbers: NC1: 12935-200, 
NC2: 12935-112 and NC3: 12935-110). 
 
 
FIGURE 1 Seven 
tiled siRNAs de-
signed to target the 
region surrounding 
the T/C single nu-
cleotide polymor-
phism (SNP) 
rs1800222 in the 
COL1A2 gene. Capital letters visualize 19 nucleotides of the 
antisense siRNA strand that are perfectly complementary to the 
T-allele of rs1800222. Each siRNA-strand had a two-nucleotide 
3-prime overhang, which is visualized as non-capital letters in 
the antisense strands of siRNAs 1-7. 
Cell culture and transfection 
Primary cultures of bone derived cells from pa-
tients undergoing hip- and knee replacement surgery 
were genotyped for a C/T single nucleotide poly-
morphism (SNP) in exon 6 of COL1A2 (SNP ID 
rs1800222) (Allele frequencies: T=0.09 A=0.91). Cells 
from a heterozygous individual were transfected in 
24-well cell plates using Magnet Assisted Transfection 
(MATRA) (Promokine, Germany). In the initial ex-
periment 75,000 cells were seeded the day prior to 
transfection which was carried out using either 0.6µg 
of each siRNA, negative control siRNA, vehicle (only 
magnetic beads) or untreated control cells, with each 
treatment performed in duplicate wells. Transfected 
cells were incubated at 37°C in 5% CO2 until RNA was 
isolated at 48 hours post- transfection. In the subse-
quent experiment, 17,000 cells were seeded three days 
prior to transfection using 0.3µg, 0.45µg and 0.6µg of 
siRNA3 or negative control siRNAs (four wells per 
treatment). The cells were then incubated for 72 hours 
until RNA was prepared. 
RNA preparation and cDNA-synthesis 
RNA was prepared using the QiaShredder kit 
and the RNeasy mini kit (Qiagen, Germany). Each in-
dividual RNA-sample was subjected to DNase treat-
ment using TURBO-DNAfree (Ambion) and equal 
amounts of RNA were then reversely transcribed with 
the High Capacity cDNA reverse transcription kit 
(Applied Biosystems). 
Polymerase Chain Reaction and sequencing 
Polymerase Chain Reaction (PCR) was used to 
amplify exons 6 and 25 of COL1A2. The primers used 
were: Exon 6 forward primer: 5’CCTACCAACATGCC 
AATCTTTAC, Exon 6 reverse primer: 
5’GTTTTCCAGGGTGACCATCTT, Exon 25 forward 
primer: 5’-AGTCCGAGGACCTAATGGAGAT, Exon 
25 reverse primer: 
5’-GCATGACCTTTATCACCGTTTT. PCR reactions 
were performed using standard PCR conditions with Int. J. Med. Sci. 2008, 5 
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an annealing temperature of 60°C. Sequencing PCR 
reactions were performed using the same primers with 
BigDye 3.1 sequencing chemistry according to the 
manufacturers instructions (Applied Biosystems). 
Assessment of relative allele abundance of COL1A2 
mRNA 
The software PeakPicker (17) was used to quan-
tify ratios of the two COL1A2 alleles for all 
cDNA-samples Briefly, for each individual 
cDNA-sequence, SNP peak-heights were normalized 
for peak heights of adjacent non-polymorphic posi-
tions. For all treatments, allele ratios of the two SNPs 
rs1800222 and rs412777 were compared to 
peak-heights of negative control siRNAs.   
Quantitative PCR 
Quantitative PCR (qPCR) reactions were per-
formed using ten µl 2x TaqMan® Universal PCR 
Master Mix, No AmpErase® UNG (Applied Biosys-
tems) was mixed with 9 µl diluted cDNA and 1 µl of 
Taq-man gene specific assay mix COL1A2: 
Hs01028967_g1,  GAPDH: Hs99999905_m1 (Applied 
Biosystems). This mix was subjected to 40 cycles of 
PCR using the ABI Prism 7900 Taqman instrument 
(Applied Biosystems). Each individual sample was 
analyzed in duplicate and COL1A2 abundance was 
normalized relative to Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) levels. 
RESULTS  
To verify the successful delivery of small RNA, 
Cy3-labeled negative control siRNAs were transfected 
to primary bone cells at the same concentration as 
were used in the silencing experiments. Successful 
delivery to the target cells is shown in Figure 2, which 
depicts a fluorescence microscopy image capture of the 
Cy3-siRNA transfected cells 72 hours 
post-transfection.  
From the silencing experiments using seven tiled 
siRNAs it was observed that siRNAs 3 and 4 were in-
duced the highest degree of allele-preferential COL1A2 
degradation (Figure 3). In a subsequent experiment 
cells were transfected with three different concentra-
tions of siRNA3, which resulted in a substantial re-
duction in rs1800222 T/C allele ratio of mRNA in some 
of the transfected wells (Figure 4). The 0.3µg dose 
rendered a mean rs1800222 T/ C allele ratio of 33%, 
and the corresponding ratios for 0.45µg and 0.6µg were 
0.30 and 0.35, respectively (Figure 5 A). These results 
w e r e  v e r i f i e d  b y  c D N A  s e q u e n c e  a n a l y s i s  o f  a  h e t -
erozygous SNP in exon 25 (rs412777) where the allele 
ratios were 0.35, 0.38 and 0.41 for 0.3µg, 0.45µg and 
0.6µg dosages of siRNA3, respectively (Figure 5A). 
Quantitative PCR analysis revealed that with increas-
ing siRNA3 dosage, COL1A2 abundance was de-
creased by 71%, 77% and 82% (Figure 5B), of which 
75%, 75% and 73% could be attributed to silencing of 
the targeted T-allele, respectively.  
 
 
FIGURE 2 Fluorescence microscope image of Cy3-labeled 
negative control siRNAs inside of primary bone cells 72 h 
post-transfection. Red colour indicates areas where siRNAs are 
present and blue regions depict cellular nuclei stained with 
DAPI.  
 
 
 
 
FIGURE 3 mRNA ratios of the two COL1A2 alleles (allele 
targeted by siRNAs vs. non-targeted allele) 48 hours 
post-transfection with seven tiled siRNAs targeting the the 
T-allele of the COL1A2 exon 6 SNP rs1800222. Shown are 
mean ratios and standard deviations, derived from PeakPicker 
analysis of cDNA chromatogram peak heights of two het-
erozygous SNPs in the COL1A2 gene (rs1800222 and 
rs412777).  Int. J. Med. Sci. 2008, 5 
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FIGURE 4 Chromatogram from sequencing of cDNA samples 
derived from RNA isolated 72h post-transfection with: (A) 
siRNA3. (B) Negative Control siRNA. 
 
 
FIGURE 5 Allele ratios of the two COL1A2 mRNA alleles 
(normalized cDNA peak heights of targeted vs. non-targeted 
allele of rs1800222) 72 hours post-transfection with three dif-
ferent concentrations of siRNA3. Colours of bars indicate the 
SNP used to calculate allele ratios from cDNA chromatograms 
in the software PeakPicker and error bars indicate standard 
deviations. (B) Relative overall COL1A2 mRNA levels fol-
lowing siRNA treatment quantified by real-time PCR. Expres-
sion levels were normalized for GAPDH levels and are pre-
sented relative to COL1A2 mRNA levels in cells treated with the 
negative control siRNAs (NC1 and NC2). Error bars indicate 
standard deviations. 
DISCUSSION 
OI is a severe genetic disease with no existing ef-
fective or curative treatment. This study was aimed at 
exploring a genetic therapeutic approach for treating 
or limiting the severity of this disease. The principle of 
allele specific silencing of Collagen type I genes has 
been explored previously by Millington-Ward (14) 
who reported allele-preferential silencing of COL1A1 
in COS7 cells and in primary human mesenchymal 
progenitor cells. The results reported by Milling-
ton-Ward can be regarded as proof of principle for the 
RNAi approach in OI treatment. 
In this study we analyzed both alleles of COL1A2 
simultaneously in primary bone cells from a single 
heterozygous individual and concluded that al-
lele-preferential silencing is possible. Results revealed 
that the 0.3µg dose of siRNA3 was as specific for the 
T-allele as the 1.5x and 2x higher concentrations, while 
seemingly exhibiting less spill-over silencing of the 
C-allele, signifying that concentration is pivotal for 
allele specificity. Although the transfection efficiency 
was not determined we show that fluorescently la-
belled negative control siRNAs were delivered to the 
bone cells when cells were transfected with the highest 
siRNA concentration that was used in the silencing 
experiments. In future studies it will be necessary to 
determine the appropriate vehicle for efficient and 
specific delivery of the allele-preferential siRNAs to 
the intended target cells in vitro, and ultimately in vivo.  
Several hurdles remain to be overcome before 
truly allele specific siRNAs, which render 50% overall 
silencing of the Collagen 1 alpha genes, can be tested in 
clinical trials. The efficiency and specificity of RNA 
interference using siRNAs is heavily dependent on the 
base composition of target sites in mRNA as well as on 
the siRNA sequences themselves. It will be necessary 
to analyze allele specificity and off-target effects of a 
large siRNA subset which target the full array of 
COL1A1 and COL1A2 polymorphisms for which the 
minor allele occurs in high enough frequencies. In ad-
dition to reducing target gene abundance, siRNAs are 
likely to also affect genes harbouring sequences par-
tially complementary to the siRNAs, which will need 
to be further analyzed in order to exclude deleterious 
off-target effects. Another challenge will be to deter-
mine how to administer siRNAs specifically to the 
target cells in sufficient quantity. Recent studies have 
reported target tissue specific expression of siRNAs in 
mice as well as in non-human primates using viral Int. J. Med. Sci. 2008, 5 
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vectors expressing short hairpin RNAs (shRNAs). 
Aptamer-shRNA chimaeras (18) may also be an inter-
esting possibility to explore in order to deliver siRNAs 
specifically to certain cell types.  
As a multitude of independent mutations (>800) 
have been described as causative of OI, it would be 
laborious to design separate allele specific siRNAs for 
each patient. We show that siRNAs differing for SNPs 
can be used to silence predominately one allele of 
COL1A2 in primary bone cells. The next step is to scan 
the full range of polymorphisms in the COL1A2 and 
COL1A1 and to design highly allele-specific siRNAs. 
By designing highly effective and specific siRNA pairs 
targeting each of two alleles of a particular SNP, rather 
than the actual mutation, the siRNA linked to the mu-
tated allele could be used therapeutically in 
OI-patients heterozygous for this SNP. With a panel of 
siRNAs against common SNPs in the Collagen type I 
genes it would be possible to genotype the patient for 
common polymorphic positions and then advance 
with the most appropriate siRNA. As proof of princi-
ple, silencing of the T-allele of rs1800222 produced 
equally evident silencing when allele ratios were ex-
amined for a polymorphic position in exon 25 (rs 
412777).  
The results presented herein show that al-
lele-preferential silencing of COL1A2 is possible in the 
desired target cells, and thus presents a framework for 
further efforts towards personalized RNAi therapy in 
OI. 
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